Phase 3 Trial Testing New Imaging Agent for Prostate Cancer Detection Doses First Patient

Phase 3 Trial Testing New Imaging Agent for Prostate Cancer Detection Doses First Patient
A Phase 3 trial evaluating Progenics Pharmaceuticals' new imaging agent to help detect prostate cancer recurrence has begun dosing participants. The agent, called PyL (18F-DCFPyl), is a tracing substance composed of the prostate specific membrane antigen (PSMA)-targeting agent DCFPyL coupled to a radioactive substance called fluorine F 18. PyL is used in positron emission tomography/computed tomography (PET/CT) imaging, a diagnostic tool that uses small amounts of radioactive materials along with a special camera and computer to help evaluate organ and tissue function. After a patient is injected intravenously (into the vein) with the tracing substance, PyL travel
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *